Introduction
Hematopoietic stem/progenitor cells (HSPCs) circulate in the peripheral blood (PB) under steady state conditions at very low levels and their number increases in emergency situations such as infection and/or tissue damage. [1] [2] [3] HSPCs could be also mobilized from bone marrow (BM) into PB after administration of some cytokines, [4] [5] [6] [7] growth factors, [8] [9] [10] [11] chemokines, [12] [13] [14] and pharmacological agents. [15] [16] [17] [18] The cytokine granulocyte colonystimulating factor (G-CSF) is currently the most frequently used clinical drug that may efficiently mobilize HSPCs after a few consecutive daily injections. Some level of mobilization has also been achieved within 1 h in experimental animals after injection of polysaccharide zymosan. [19] [20] [21] Generally, all mobilizing agents induce a proteolytic environment in BM tissue. [22] [23] [24] [25] However, the molecular mechanisms controlling egress of HSPCs from BM into PB are still not well understood. Nevertheless, it is widely accepted that what is crucial for the BM egress of HSPCs is the attenuation of the stromal-derived growth factor-1 (SDF-1)-CXCR4 interaction between BM-secreted SDF-1 and HSPC-expressed CXCR4 and the adhesive interaction between very late antigen-4 (VLA-4; a 1 b 4 integrin) expressed on HSPCs and its ligand vascular adhesion molecule-1 (VCAM-1; CD106), which is expressed in the BM microenvironment. 26, 27 Nevertheless, a significant number of patients, particularly those pretreated by chemotherapy, are resistant to G-CSF mobilization. 28 This explains why new pro-mobilizing compounds are tested as being used alone or in combination with G-CSF. One such compound is bicyclam AMD3100, which blocks the interaction between CXCR4 and SDF-1.
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On the other hand, augmenting evidence shows that HSPC mobilization is regulated by elements of innate immunity, in particular by complement cascade (CC) protein cleavage fragments, [32] [33] [34] [35] [36] [37] neutrophils, [38] [39] [40] [41] and Toll receptors 42 that all have a pivotal and, until recently, underappreciated function in this process. Accordingly, we reported that CC becomes activated in BM during mobilization of HSPCs by the immunoglobulin (Ig)-dependent pathway and/or by the alternative Ig-independent pathway as seen, for example, during G-CSF-or zymosan-induced mobilization, respectively. 33, 34 To support this notion, we found that (i) non-obese diabetic/severecombined immune deficient (SCID) and Rag À/À animals that do not activate the Ig-dependent CC classical pathway; 37 (ii) C2 and factor B-deficient (C2.Cfb À/À ) mice that do not activate the classical and alternative CC pathways; 3 and (iii) C5 À/À mice that do not activate the distal pathway of CC are all poor G-CSF and/ or zymosan mobilizers. 40, 41 Moreover, our studies in C5-deficient mice revealed that C5 cleavage fragments (C5a and desArg C5a) are crucial for the egress of HSPCs, and we postulated three levels at which they affect this process. 41 First, stimulation of granulocytes directly in the BM microenvironment by C5a and desArg C5a enhances secretion of proteolytic enzymes, which perturb HSPCs retention signals (e.g. SDF-1-CXCR4 and VLA-4-VCAM-1 interactions). Second, the plasma desArg C5a strongly chemoattracts granulocytes. These granulocytes migrating from BM into PB highly express metalloproteinases (MPs) and 'pave the way' through the endothelial barrier for HSPCs, which follow granulocytes (ice breaker phenomenon). Finally, after egress from BM, granulocytes are stimulated in BM vessels by C5a and release several cationic peptides (e.g. cathelicidin and b2-defensin), some of which enhance/prime responsiveness of HSPCs to plasma SDF-1. 41 In this study, we were interested in the novel-mobilizing agent AMD3100. As the primary target of this compound is CXCR4 expressed on BM-residing cells, we asked whether mobilization of HSPCs by this compound involves activation of CC as well. We found that AMD3100-directed mobilization, similarly to G-CSF-induced mobilization, depends on activation of CC; however, in contrast to G-CSF, AMD3100 activates CC at the distal stages directly at the C5 level by proteases released from activated granulocytes. Thus, our data further support the concept that C5 cleavage is crucial for optimal egress of HSPCs from BM.
Materials and methods

Animals
Pathogen-free, 4-to 6-week-old C5 À/À , C5 þ / þ , and Rag À/À mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA; http://www.jax.org). C57BL/6, Balb/c, and SCID mice were purchased from the National Cancer Institute (Frederick, MD, USA; http://www.cancer.gov). C2.Cfb À/À mice were a kind gift from Dr M Botto (Imperial College, London, UK). All mice were adopted by at least 2 weeks and used for experiments at age 6-8 weeks. Animal studies were approved by the Animal Care and Use Committee of the University of Louisville (Louisville, KY, USA).
Mobilization
Mice were injected subcutaneously (s.c.) with 250 mg/kg of human G-CSF (Amgen, Thousand Oaks, CA, USA; http:// www.amgen.com) daily for 6 days. For zymosan mobilization, mice were injected intravenously with 0.5 mg per mouse. For AMD3100 mobilization, animals received this compound at a dose of 5 mg/kg s.c. At 6 h after the last G-CSF administration or at 1 h after zymosan and AMD3100 injection, mice were bled from the retro-orbital plexus for complete blood count and 450 ml of PB was obtained from the vena cava with a 25-gauge needle and 1 ml syringe containing 50 ml of 100 mM ethylenediaminetetraacetic acid.
Complete blood counts
Fifty microliters of PB was taken from the retro-orbital plexus of the mice and collected into microvette ethylenediaminetetraacetic acid-coated tubes (Sarstedt Inc., Newton, NC, USA; http:// www.sarstedt.com/php/main.php). Samples were run within 2 h of collection on a HemaVet 950 (Drew Scientific Inc., Oxford, CT, USA; http://www.drew-scientific.com).
Colony-forming unit-granulocytes/macrophage assay
Red blood cells were lysed with BD Pharm Lyse buffer (BD Biosciences, San Jose, CA, USA; http://www.bdbiosciences.com). Nucleated cells were subsequently washed twice and used for colony-forming unit-granulocytes/macrophage (CFU-GM) colonies as described elsewhere. Briefly, cells were resuspended in human methylcellulose base media provided by the manufacturer (R&D Systems, Inc., Minneapolis, MN, USA; http:// www.rndsystems.com) supplemented with 25 ng/ml recombinant murine granulocyte macrophage colony-stimulating factor and 10 ng/ml recombinant murine interleukin-3 (Millipore, Billerica, MA, USA; http://www.millipore.com). Cultures were incubated for 7 days, at which time they were scored for the number of CFU-GM colonies under an inverted microscope.
Evaluation of HSPC mobilization
The following formula was used for evaluation of circulating CFU-GM and Sca-1 
BM-nucleated cells
BM-nucleated cells (BMNCs) were prepared by flushing femurs and tibias of pathogen-free, 6-to 8-week-old mice without enzymatic digestion. BMNCs were lysed with BD Pharm Lyse buffer (BD Biosciences) to remove red blood cells, washed, and resuspended in appropriate media for further analysis.
Fluorescence-activated cell sorting analysis
BMNC staining was performed in medium containing 2% fetal bovine serum. All monoclonal antibodies were added at saturating concentrations and the cells were incubated for 30 min on ice, washed twice, resuspended in staining solution at a concentration of 5 Â 10 6 cells/ml, and subjected to analysis using an LSR II (Becton Dickinson, Mountainview, CA, USA). The following anti-mouse Abs were used to detect fluorescein isothiocyanate-anti-CD117 (c-Kit) (clone 2B8; BioLegend, San Diego, CA, USA) and phycoerythrin-Cy5 anti-mouse Ly-6A/E (Sca-1) (clone D7; eBioscience San Diego, CA). All anti-mouse lineage markers (Lin) were conjugated by phycoerythrin and purchased from BD Biosciences: anti-CD45R/B220 (clone RA3-6B2); anti-Gr-1 (clone RB6-8C5); anti-t-cell receptor b (clone H57-597); anti-t-cell receptorgd (clone GL3); anti-CD11b (clone M1/70); anti-Ter-119 (clone TER-119); and anti-CD34 (clone RAM34).
Sorting of BMNCs
Granulocytes (Gr-1 þ ) were purified as described elsewhere. Briefly, BMNCs (1 Â 10 8 cells/ml) were resuspended in Roswell Park Memorial Institute medium containing 2% heat-inactivated fetal bovine serum (GIBCO, Grand Island, NY, USA), 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid buffer (GIBCO), and antibiotics (Mediatech Inc., Manassas, VA, USA; http://www.cellgro.com). Next, BMNCs were incubated with saturating concentrations of directly labeled monoclonal antibodies for 30 min on ice, washed twice, and sorted by multiparameter, live sterile cell sorting (MoFlo; Dako A/S, Fort Collins, CO, USA).
Zymography
To evaluate matrix (M)MP-9 secretion by Gr-1 þ cells, 2 Â 10 6 cells/ml were incubated (for 24 h at 37 1C in 5% CO 2 ) in the absence or presence of AMD3100 (1 mM) and cellconditioned media were analyzed immediately by zymography as described earlier. 43 The relative quantitation value of the target, normalized to an endogenous control gene (b-2 microglobulin) and relative to a calibrator, is expressed as 2 -DDCt (fold difference), in which DCt equals the Ct of the target genes minus the Ct of the endogenous control gene (b-2 microglobulin), and DDCt equals the DCt of the samples for the target gene minus the DCt of the calibrator for the target gene. To avoid the possibility of amplifying the contamination of DNA, a uniform amplification of the products was rechecked by analyzing the melting curves of the amplified products (dissociation graphs): the melting temperature (Tm) was 57-60 1C, the product Tm was at least 10 1C higher than the primer Tm.
Phosphorylation of intracellular pathway proteins
Enzyme-linked immunosorbent assay for complement cleavage fragment detection
Whole blood from C57BL/6 mice was obtained from the vena cava (1 ml syringe containing 50 ml of 100 mM ethylenediaminetetraacetic acid) at various time points after PBS, AMD3100, or zymosan treatment. Plasma samples were prepared by taking the top fraction after centrifugation at 1000 g for 10 min at 4 1C. Some normal plasma from C57BL/6 mice was stimulated with AMD3100 in the presence or absence of purified Gr-1 þ cells (10 5 cells) at 37 1C for up to 30 min. Samples were stored at -80 1C until use. All Abs, standard proteins, enzyme reagents, and substrate solutions were purchased from BD Biosciences. Assays were performed according to general instructions. Briefly, plasma samples were incubated in triplicate wells of microtiter plates, which had been pre-coated with antigenspecific capture Abs (C3a or C5a). Repeated washing and aspiration were conducted before each incubation step to remove unbound materials from the assay plates. This step was followed by incubation with specific biotin-labeled capture Abs and an enzyme reagent. Substrate solution was added to the wells of the microtiter plates and color developed in proportion to the amount of antigen bound in the initial step of the individual assay. The color development was stopped with the addition of an acid solution and the intensity of color was read using a microtiter plate spectrophotometer. The concentrations of complement C3a or C5a in plasma samples were determined by interpolation from individual standard curves composed of purified human C3a or C5a. Purified rat anti-mouse-C3a (clone I87-1162) or -C5a (clone I52-1486) Abs was used as the capture Ab, respectively (2 mg/ml, overnight at 4 1C). Biotin-labeled rat anti-mouse-C3a (clone I87-419) or -C5a (clone I52-278) Abs was used as the detection Ab (2 mg/ml, 2 h at room temperature). Plasma samples were used at a 1:20 or 1:10 dilution for C3a or C5a detection, respectively.
Statistical analysis
Arithmetic means and standard deviations were calculated using Instat 1.14 software (Graphpad, San Diego, CA, USA). Statistical significance was defined as Po0.05. Data were analyzed using Student's t-test for unpaired samples.
Results
AMD3100 restores proper mobilization in Rag
À/À , SCID, and C2.Cfb À/À mice that do not activate the proximal steps of CC, but is less effective in C5 À/À animals We reported that Ig-deficient mice that do not activate complement by the classical pathway are poor G-CSF-induced mobilizers. 37 In a current study, we mobilized these mice by AMD3100 and to our surprise noticed that they mobilize a similar number of CD34
À SKL À cells, CFU-GM progenitors, and leukocytes as their wild type littermates ( Figure 1) .
Next, we used C2.Cfb À/À animals that possess defects at the upstream steps of CC activation by both classical (C2 deficiency) and alternative (factor B deficiency) pathways. As expected, we found that these mice are poor zymosan (Figure 2, upper panel) and G-CSF (middle panel) mobilizers; however, they are normal mobilizers after administration of AMD3100 (Figure 2, lower panel) .
Finally, we performed mobilization in C5 À/À animals that are not able to generate the distal components of CC activation, that is C5a and desArg C5a. In our earlier work, we reported that these animals are poor G-CSF-and zymosan-induced mobilizers, which points to C5 cleavage fragments as being crucial for optimal HSPC egress. 40, 41 However, we report here that these animals are poor AMD3100 mobilizers (Figure 3) , which is in contrast to mice with defects in activation of the proximal steps of CC activation. This indicates that C5 cleavage fragments are crucial for the optimal egress of HSPCs. We hypothesized that normal AMD3100 mobilization in animals with defects in activation of the proximal steps of CC suggests that C5 is activated/cleaved in these animals by some alternative mechanism.
AMD3100 activates CC at the distal C5 level; potential involvement of granulocytes?
Next, we evaluated activation of CC in plasma at the proximal C3 and distal C5 level in normal animals mobilized by AMD3100 or zymosan. The concentration of C3 and C5 cleavage fragments, C3a/ desArg C3a and C5a/ desArg C5a, respectively, was Figure 4 AMD3100 mobilization activates C5 cleavage and leukocytes precede egress on HSPCs during AMD3100 mobilization. The concentration of C3 and C5 cleavage fragments, C3a/ desArg C3a and C5a/ desArg C5a, respectively, was measured by ELISA. Zymosan, but not AMD3100 or PBS administration, activates CC at the C3 level (A), *Po0.01. In contrast, CC is activated at the C5 level by both zymosan and AMD3100; however, zymosan seems to be a much more potent C5 activator (B), *Po0.01. (C) Kinetics of mobilization of leukocytes (WBC) (a), neutrophils (NE) (b), monocytes (Mo) (c), and CFU-GM progenitors (d) in mice mobilized 0-90 min after administration of AMD3100 (5 mg/kg s.c.). Data are pooled from two independent experiments with six animals per experimental point. *Po0.0001.
Innate immunity and stem cell mobilization HM Lee et al measured by enzyme-linked immunosorbent assay (ELISA). Figure 4A shows that AMD3100, in contrast to zymosan, does not activate CC at the C3 level. However, CC is activated at the C5 level both by AMD3100 and zymosan, but zymosan seems to be a much more potent C5 activator ( Figure 4B ).
The activation of C5 by AMD3100 was an intriguing question. On the basis of the data in the literature, we hypothesized that C5 can be alternatively cleaved in BM sinusoids by proteases secreted by mobilized neutrophils and monocytes. [44] [45] [46] [47] Thus, we became interested in the potential function of AMD3100 granulocyte-dependent activation of CC. Figure 4C cell egress kinetic data show that granulocytes and monocytes are the first cells mobilized into PB by AMD3100 and that their egress precedes mobilization of HSPCs ( Figure 4C ).
AMD3100 directly activates granulocytes that cleave/ activate C5
As AMD3100 perturbs the interaction of CXCR4 with SDF-1 in the BM microenvironment, we asked which additional steps of mobilization are affected by AMD3100. In particular, we were interested if mobilized phagocytic cells accumulating in PB before HSPCs ( Figure 4C ) could be a source of C5-activating proteases.
First, we found that AMD3100 has no chemotactic activity against BM cells (data not shown); it activates phospohorylation of MAPKp42/44 in these cells (Figure 5a ). This observation is supported by a report that AMD3100 is a partial CXCR4 agonist. 48 Next, we noticed by using zymography that Gr-1 þ phagocytic cells isolated from BM respond to stimulation of AMD3100 by secretion of metalloproteinases (MMPs) (Figure 5b ). Figure 5c also shows that MMP-9 activity is elevated in PB from AMD3100-mobilized mice. Finally, real-time quantitative polymerase chain reaction (RQ-PCR) revealed that AMD3100 upregulates in BM-derived Gr-1 þ cells expression of mRNA for MMP-9, cathepsin G, and neutrophil elastase (Figure 5d) .
Finally, to prove that phagocytic cells may secrete enzymes that activate/cleave C5, we sorted a population of Gr-1 þ cells (Figure 6a ) from BM by fluorescence-activated cell sorting, stimulated them or not by AMD3100, and subsequently exposed normal murine plasma to these cells. By using a sensitive ELISA assay, we noticed that these cells in fact activated/cleaved C5 (Figure 6b ).
Discussion
The process of HSPC mobilization is still not fully understood and a significant number of patients, particularly those with earlier histories of chemotherapy, are poor G-CSF mobilizers. Several host-related factors have been described to regulate mobilization, including (i) release of proteases in the BM microenvironment by activated myeloid cells, which perturb interactions of SDF-CXCR4, 23, 25 VLA-4-VCAM-1, 26,27 and KL-c-KitR axes; [49] [50] [51] (ii) release of neurotransmitters in the BM microenvironment by neural fibers that innervate BM tissue; 52 (iii) downregulation of SDF-1 expression in osteoblastic stem cell niches; 53, 54 (iv) activation of osteoclasts; 55 and (v) upregulation of serpin family protease inhibitors. 56 Recent evidence from our laboratory shows that mobilization of HSPCs is regulated by several components of innate immunity including CC and granulocytes. 3, 41 Accordingly, we reported that, for example, G-CSF and cyclophosphamide strongly activate CC in BM by a classical pathway because of exposure during mobilization of neoepitope on the surface of damaged BMNCs. 36, 37, 57, 58 This neo-epitope binds naturally occurring (N)Abs and subsequently neo-epitope-NAb complexes circulating in PB through C1q to trigger the classical Ig-dependent pathway of CC activation. In contrast, zymosan as a polysaccharide may directly activate CC by using factor B and D involving the Ig-independent alternative CC activation pathway. The crucial function of CC in mobilization of HSPCs was shown in experiments in mice with various defects of CC activation (e.g. Ig-deficient SCID and Rag À/À , C2.Cfb À/À , and C5 À/À animals). Granulocytes as a source of proteolytic enzymes in the BM that perturb HSPC retention signals (SDF-CXCR4, VLA-4-VCAM-1, and KL-c-KitR axes) are another important component of innate immunity required for HSPC mobilization. To support this, it was reported that mobilization of HSPCs is severely reduced in neutropenic mice. 13, 14, 39 The pivotal function of CC activation and granulocyte activation/egress was recently reported by us to be perturbed in C5-deficient mice. Accordingly, we described that activation of CC in response to a mobilizing agent (G-CSF or zymosan) leads to C5 clevage and that C5 clevage fragments C5a and desArg C5a through BM-granulocytes orchestrate egress of HSPCs into PB. We noticed that C5a stimulates BM-granulocytes to secrete proteases, which contribute with other factors to establish a proteolytic environment on BM. 40, 41 Next, desArg C5a activated in BM sinusoids chemoattracts granulocytes that egress from BM as a first wave of cells to 'pave the way' for Innate immunity and stem cell mobilization HM Lee et al HSPCs that follow. Finally, granulocytes mobilized into PB release several cationic peptides that increase responsiveness of HSPCs to SDF-1. AMD3100 (plerixafor) is a bicyclam with two 1,4,8,11-tetraazacyklotetradecyne (cyclam) rings linked by 1,4-phenylenbis(methylene) moiety that is currently used as an efficient mobilizing agent alone or in combination with other drugs (e.g. G-CSF). On the basis of its different molecular action as compared with G-CSF or zymosan, we asked whether optimal AMD3100-induced mobilization also depends on CC activation. To address this question, we used mice that possess a defect in the activation of the proximal (SCID, Rag À/À , and C2.Cfb À/À mice) as well as distal (C5 À/À mice) steps of CC. We also directly evaluated activation of CC at the proximal C3 and distal C5 levels by using an ELISA assay to determine the presence of cleavage fragments in plasma of AMD3100-mobilized mice. We learned that mice with a defect in the activation of the proximal steps of CC mobilize normally; however, mobilization was still impaired in C5 À/À mice. Furthermore, our ELISA studies revealed that after AMD3100 administration, C5, but not C3, is cleaved/activated in the plasma of these animals.
On the basis of these observations, we hypothesized that during AMD3100 mobilization, C5 could be cleaved in a cascade-independent, non-canonical manner. We also paid close attention to Gr-1 þ phagocytic cells (granulocytes and monocytes), which are able to cleave/activate C5 as reported. [44] [45] [46] [47] In fact, we noticed that granulocytes and monocytes are the first cells that egress from BM during AMD3100 mobilization.
To address this issue, we studied the influence of AMD3100 stimulation on Gr-1 þ cells sorted from BM that are enriched in granulocytes and monocytes and found that AMD3100 activates phosphorylation of MAPKp42/44 in these cells. This could be explained by AMD3100 being a partial agonist of CXCR4. 48 Of importance, we identified for the first time that AMD3100 stimulates expression/secretion of several proteases (e.g. MMP-9, cathepsin, elstaze) in a Gr-1 þ population. More importantly, in a direct set of experiments, we observed that C5 is cleaved/activated in plasma by Gr-1 þ cells and that stimulation of these cells by AMD3100 enhances this effect. Altogether, these observations support the idea that mobilized/ activated granulocytes activate the distal steps of CC in PB by inducing cleavage of C5. Thus, our data again confirm that C5 clevage fragments C5a and desArg C5a orchestrate optimal mobilization of HSPCs after AMD3100 administration.
On the basis of these observations, we envision a flowing scenario in mobilization and CC activation induced by AMD3100 (Figure 7) . First, at the BM microenvironment level, AMD3100 blocks the interaction of CXCR4 þ granulocytes and CXCR4
þ HSPCs with SDF-1 expressed in the BM microenvironment. At the same time, AMD3100 stimulates secretion in BM of MMPs and other proteolytic enzymes from activated granulocytes that help to perturb another axis crucial in HSPCs retention, that is VLA-4-VCAM-1. Next, granulocytes are the first cells to egress from BM and they 'pave the way' for HSPCs to cross the BM-endothelial barrier. Finally, granulocytes activated/mobilized by AMD3100 into PB activate/cleave C5 and release C5a and desArg C5a that subsequently orchestrate/ facilitate the final steps of HSPC egress.
In conclusion, our data (i) better explain molecular mechanisms directing AMD3100-induced mobilization; (ii) support a central function of innate immunity; and (iii) provide evidence that C5 is activated/cleaved in plasma in a Gr-1 þ celldependent manner. Granulocytes and C5 cleavage fragments orchestrate this process and, in light of our current data, mobilization of HSPCs could be envisioned as a part of the innate immunity response. However, further studies are needed to address if, in addition to C5a and desArg C5a cleavage fragments, other elements downstream from C5 of CC, for example C5b-C9 and/or membrane attack complex, are involved in the mobilization process.
Conflict of interest
The authors declare no conflict of interest. 
Proteases
Stimulation Endothelium
Figure 7 AMD3100-directed HSPC mobilization depends on activation of CC by AMD3100 mobilized/activated granulocytes. We envision three potential steps at which AMD3100 induces HSPC mobilization. First, AMD3100 blocks the interaction of CXCR4 þ granulocytes and CXCR4
þ HSPCs with SDF-1 expressed in the BM microenvironment. At the same time, however, AMD3100 stimulates secretion of MPs in BM from activated granulocytes, which helps to perturb/block another retention axis for HSPCs in BM, that is the VLA-4-VCAM-1 interaction (Step I). Next, granulocytes are the first cells to egress from BM and they 'pave the way' for HSPCs to cross the BM-endothelial barrier (ice breaker phenomenon;
Step II). Finally, proteolytic enzymes released from AMD3100-activated granulocytes in BM sinusoids activate/cleave CC at the distal stages (i.e. C5) resulting in the release of C5a and desArg C5a, which facilitate the final steps of HSPC egress. Further studies, however, require potential involvement of C5b-C9Fmembrane attack complex (MAC) and our data indicate that some factors generated in plasma by activated MAC chemoattract HSPCs in the presence of AMD31000 in CXCR4-independent manner (manuscript in preparation) ( Step III).
